Big pharmaceutical companies face upcoming patent expiries on major drugs between now and 2030 that will put tens of billions in sales at risk. Companies are developing new drug formulations, pursuing acquisitions, and expanding pipelines to offset expected revenue declines from patent expiries. Biosimilars have had less market impact than generics so far, but will gradually cut into biologic revenues over time. Medicare's new drug price negotiation program adds uncertainty but may affect pre-patent expiry revenues more than post-patent competition.
Category
🗞
NewsTranscript
00:00 It's Benzinga and here's what's on the block.
00:02 Big pharmaceutical companies face upcoming patient expiries on major drugs between now
00:06 and 2030 that will put tens of billions in sales at risk.
00:09 Companies are developing new drug formulations, pursuing acquisitions, and expanding pipelines
00:13 to offset expected revenue declines from patient expiries.
00:16 Biosimilars have had less market impact than generics so far, but will gradually cut into
00:20 biologic revenues over time.
00:21 Medicare's new drug price negotiation program adds uncertainty, but may affect pre-patient
00:26 expiry revenues more than post-patent competition.
00:28 For all things money, visit Benzinga.com.
00:30 (whooshing)